Cooperative Agreement 2436414
Award Date
7/15/25
Completion Date
6/30/27
Dollars Obligated
$1.2M
Federal Agency
National Science Foundation
Awardee
Superior Nano LLC (J1A3A7S6J4H7)
Federal Grant Program
47.084
Assistance Type
Cooperative Agreement
Place of Performance
St Paul, MN 55114, USA
Similar Awards
Superior Nano LLC received a $512,000 National Science Foundation Project Grant to develop dense nanolipid fluid systems for delivering drugs with poor bioavailability. The NSF funding supports research from June 2022 to May 2023 under the Technology, Innovation, and Partnerships program. This award will allow Superior Nano to advance scientific understanding of surfactant-lipid-water systems and create new knowledge applicable to manufacturing drug nanoparticles using twin-screw extrusion. By...
This National Science Foundation (NSF) Cooperative Agreement under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program provides $1,016,000 in funding to Nostopharma LLC to develop an innovative, sustained-release, and biodegradable drug delivery platform for localized treatment of post-traumatic injuries. The goal is to create a medication delivery system using anti-inflammatory nanoparticles embedded with a Hedgehog pathway antagonist, arsenic trioxide, to address unmet...
This Cooperative Agreement award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program provides $1,000,000.00 in funding to Simmbion LLC to develop a "living pharmacy" technology for treating diabetes and obesity in cats. The project aims to demonstrate the safety and tolerability of a designer organism that can function as a long-acting treatment delivered through a single injection, providing 12 weeks or more of...
Nano Pharmasolutions, Inc. received a $275,961 Project Grant award from the National Science Foundation Division of Industrial Innovation under the Engineering federal grant program (CFDA 47.041). The grant funds the development of a novel nanoformulation drug delivery platform to address challenges associated with poorly soluble drugs. The goal is to improve drug solubility and bioavailability through innovative formulation approaches. The one-year project period runs from August 1, 2021...
The National Science Foundation awarded Diant Pharma Inc. a $256,000 Project Grant under the Engineering (47.041) federal grant program. The grant will support development of an advanced continuous manufacturing system for nucleic acid lipid nanoparticles to improve supply chains for therapeutics and vaccines. Specifically, the small business innovation research Phase I project aims to create a compact, end-to-end manufacturing platform that follows current good manufacturing practices. This...
Nostopharma LLC was awarded a $256,000 Small Business Technology Transfer Phase I Project Grant from the National Science Foundation to develop a sustained-release, biodegradable nanoparticle drug delivery system for treatment of soft tissue trauma complications. Funded under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084), the 12-month project beginning March 1, 2022 aims to demonstrate in vitro and in vivo feasibility of modulating the ectopic bone microenvironment...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Delaqua Pharmaceuticals, Inc. aims to enhance the therapeutic use of hydrophobic drugs through a polymeric micelle approach to drug solubilization. The key objectives are to 1) improve the formulation of spherical micelles for enhanced stability and drug solubilization, 2) perform initial toxicity studies to establish the safety of the platform, and 3) demonstrate...
This Project Grant award, provided by the National Science Foundation (NSF) under its Mathematical and Physical Sciences (CFDA 47.049) program, supports a collaborative research effort to develop microenvironment-sensitive polymeric nanoparticles. The goal is to create nanoparticles that can simultaneously enable targeted drug delivery and provide enhanced ultrasound imaging capabilities. The $272,799 award, effective June 1, 2025 through August 31, 2026, will fund the design and mechanistic...
This Project Grant award of $305,000 from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program will support the development of a novel mammalian cell-based nano-biological coating for implantable medical devices at Novaurum Biosciences Incorporated in Somerville, MA. The project aims to address the critical issue of implant-related infections, which cost the U.S. healthcare system over $8.6 billion annually, by creating a biocompatible and...
The National Science Foundation (NSF) awarded a $275,000 Small Business Innovation Research (SBIR) Phase I project grant to Agil Therapeutics Inc. under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084). This two-year project aims to develop a novel cryoablation system for minimally invasive treatment of type 2 diabetes. The system is designed to deliver a highly controlled and targeted cryogenic agent to the duodenum, with the goal of remodeling the duodenal tissue to...